Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Net Margin (2016 - 2025)

Historic Net Margin for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 13.52%.

  • Protalix BioTherapeutics' Net Margin fell 45000.0% to 13.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.82%, marking a year-over-year increase of 298500.0%. This contributed to the annual value of 5.49% for FY2024, which is 24800.0% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Net Margin of 13.52% as of Q3 2025, which was down 45000.0% from 1.05% recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Net Margin peaked at 46.21% during Q2 2023, and registered a low of 176.89% during Q2 2021.
  • Over the past 5 years, Protalix BioTherapeutics' median Net Margin value was 32.66% (recorded in 2023), while the average stood at 34.09%.
  • Per our database at Business Quant, Protalix BioTherapeutics' Net Margin plummeted by -1387100bps in 2021 and then surged by 1159600bps in 2022.
  • Over the past 5 years, Protalix BioTherapeutics' Net Margin (Quarter) stood at 77.37% in 2021, then skyrocketed by 52bps to 37.25% in 2022, then plummeted by -55bps to 57.64% in 2023, then skyrocketed by 162bps to 35.65% in 2024, then plummeted by -62bps to 13.52% in 2025.
  • Its Net Margin stands at 13.52% for Q3 2025, versus 1.05% for Q2 2025 and 35.79% for Q1 2025.